How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Tafamidis for treating transthyretin amyloidosis with cardiomyopathy

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about tafamidis

Marketing authorisation indication

2.1 Tafamidis (Vyndaqel, Pfizer) is indicated for 'the treatment of wild‑type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM)'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics.

Price

2.3 The price of tafamidis is £10,685.00 per 30-capsule pack of 61 mg capsules (excluding VAT; company submission). The company has a commercial arrangement, which would have applied if the technology had been recommended.